Category Archives: updates

ThoughtLeader Intelligence in 90 sec

mdoutlook-tl-intelligence-banner-728x90-2

Join other oncology science professionals in benefiting from MDoutlook’s ThoughtLeader Intelligence platform for more informed, quicker decision-making. Gain access to over 100,000 oncologists, cancer treaters and identified, ranked and profiled ThoughtLeaders. Explore the oncology treater landscape in all cancers for every important market.
For a quick, 90-sec tour, check out our new video.

For more information or to schedule a demo of our oncology intelligence portal, contact us at info@mdoutlook.com or +1.404.496.4136.

Oncology Life Cycle Intelligence

MDoutlook Total Oncology Intelligence

Speak with the cancer and commercialization experts at MDoutlook about answering your critical questions that arise throughout the life cycle of your brand or service. Oncology is an increasingly complex area, because of the rapidly evolving multi-disciplinary approach to disease management and the intricate diagnosis and treatment of this disease.

Our team of MD and PhD medical analysts, MBA-level commercialization experts and support team of data and research analysts has delivered more than 450 cancer intelligence projects since 2008.

Powered by MDoutlook’s proprietary panel of 95,000 verified and profiled cancer treaters, MDoutlook will address your needs:
Early: Disease Landscape, ThoughtLeader Identification
Pre-Launch: Competitive Intelligence, Concept testing, Segmentation
Launch: KPI Tracking, Adoption Drivers and Barriers, Targeting
Maximization: KPI Tracking, Market Expansion, Competitive Intelligence

Review the latest fact sheet on our Oncology Life Cycle Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your oncology intelligence needs.

Oncology Intelligence: Innovative Solutions to Meet Your Complex Issues

MDoutlook Total Oncology Intelligence Sq

Since 2008, MDoutlook has built the largest panel of verified cancer treaters in the world. Now at over 95,000 members strong, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer.

MDoutlook offers clients a range of services powered by this proprietary oncology panel to address the needs of clinical, commercial and business development verticals at life science organizations.

Unlock this Total Oncology Intelligence to answer your questions.

Our team brings the experience of over 450 cancer intelligence projects to the bespoke and syndicated insight our clients require. Access the latest fact sheet on our Total Oncology Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Unlock Total Oncology Intelligence

MDoutlook Total Oncology Intelligence Sq

Since 2008, MDoutlook has built the largest panel of cancer treaters in the world. With more than 85,000 cancer treaters verified and profiled, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer.

MDoutlook has developed a suite of offerings built on this proprietary oncology panel to address the needs of clinical, commercial and business development functions at life science organizations.

Unlock this Total Oncology Intelligence to answer your questions.

Our team brings the experience of over 400 cancer intelligence projects to the bespoke and syndicated insight our clients require. Access the latest fact sheet on our Total Oncology Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Understand the ThoughtLeaders Who Really Impact

Built upon years of experience and appreciating the multi-factorial complexity of identifying and engaging ThoughtLeaders, MDoutlook has developed robust algorithms to capture all attributes of a ThoughtLeader’s impact on the market.

MDoutlook delivers 360° profiles of identified ThoughtLeaders, uniquely meshing public and proprietary data. Through our exclusive ThoughtLeader Attribute Dial™, clients can rank ThoughtLeaders targeted by their internal stakeholder and desired type of engagement with the ThoughtLeader. Innovative visualization provides important insights and highlights clusters of relevant collaboration.

Deliverables range from databases and flat files, to data-streams into existing client systems, to accessing MDoutlook’s integrated web-based platform.

Download the latest fact sheet on our ThoughtLeader Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Assessing the Clinical Impact of Market Developments

MDoutlook supports dozens of clients in understanding the real changes in clinical practice.

Driven by a proven methodology, engaging proprietary panels of validated and qualified healthcare providers, our team delivers meaningful insights to life science clients: from large to small, from mainstream pharma to biotech, and from medicine to technology and everything in between.

Download the latest fact sheet on our Clinical Impact Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Breast Cancer – Clinical Impact of ESMO 2014

MDoutlook has released key insight from ESMO 2014, describing the significant clinical impact of new data presented in Breast Cancer (BRCA). Results from two key clinical trials (CLEOPATRA and CherLOB) have been reviewed and commented on by more than 100 medical oncologists focused on Breast Cancer from 29 countries.

Our most recent latest research uncovers that:

Impact of the Phase III Cleopatra Study:
• In the next year, 52% of EU/RoW oncologists expect to use Trastuzumab + Pertuzumab. Additionally, 55% of EU/RoW oncologists expect to use Trastuzumab emtansine for their HER2+ metastatic breast cancer patients (in all lines of therapy)
• In the next year, only 39% of US oncologists expect to use Trastuzumab + Pertuzumab for their HER2+ metastatic patients (in all lines of therapy), while 64% expect to use Trastuzumab emtansine
• When Trastuzumab + Pertuzumab is used, ~75% of both US and EU/RoW oncologists expect to use it as a first line therapy for their HER2+ metastatic patients (in all lines of therapy)

Impact of the CherLOB Study:
• The majority of US and EU/RoW oncologists believe the data presented in the CherLOB study is clinically important
• US oncologists intend to increase PIK3CA testing by ~400% for their early and metastatic breast cancer patients
• EU/RoW oncologists intend to increase PIK3CA testing for their early breast cancer patients by ~2200%

Request your complimentary copy of the 2014 ESMO OncoPoll – Breast Cancer report here. You will receive an email with the download link.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with all our colleagues.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Contact us to discuss how MDoutlook can answer your disease intelligence needs.

MDoutlook identifies and engages with cancer treaters of all disciplines, clinical interest, practice setting, and ThoughtLeader status. Since our start in 2008, we have profiled more than 6,500 global oncology ThoughtLeaders, identifying their National, Local and Referral ThoughtLeader rankings.

With the ASCO Breast Cancer Symposium in San Francisco this month, we thought it useful to share some highlights of our US-focused ThoughtLeader research in breast cancer:

  • 125+ National ThoughtLeaders
  • 700+ Local ThoughtLeaders
  • 700+ Referral ThoughtLeaders – “Who do you refer your patients to for treatment?” 

The top 8 referral ThoughtLeaders in Breast Cancer in the US
Top 8 Referral ThoughtLeaders in Breast Cancer

Further analysis of the physician referral patterns, yields the following the Top US referral institutions for breast cancer:

1. Memorial Sloan Kettering Cancer Center
2. Dana-Farber Cancer Institute
3. University of California San Francisco Medical Center
4. University of Texas MD Anderson Cancer Center
5. Mayo Clinic
6. Stanford University Hospital
7. Duke University Medical Center
8. Northwestern Memorial Hospital
9. UCLA Medical Center
10. University of Michigan Medical Center

MDoutlook’s methodology utilizes a proprietary and integrated peer-nomination system allowing for prominence of clinical reputation via peer ranking. Employing the unique MDoutlook ThoughtLeader Attribute Dial™, additional criteria are weighed such as:

  • Publication and clinical trial
  • Leadership
  • Professional profile
  • Public profile
  • And other client-specific factors

For more information or to discuss how we can support your work in breast cancer and other areas of oncology, please contact Craig Krugman (+1.404.452.5988). Or do connect with him at the upcoming ASCO Breast Cancer meeting in San Francisco.